Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269011 | 0.95 | PIK3CD (0.32) | PIK3CDMCHR1 | |
| SCHEMBL31268901 | 0.93 | PIK3CD (0.33) | PIK3CDMCHR1 | |
| SCHEMBL31269027 | 0.93 | PIK3CD (0.32) | PIK3CDMCHR1THRBNPC1RAB9A | |
| SCHEMBL31268837 | 0.91 | KDM4E (0.33) | PIK3CDNPC1RAB9A | |
| SCHEMBL31269166 | 0.90 | ALDH1A1 (0.40) | PIK3CDNPC1RAB9A | |
| SCHEMBL31268824 | 0.90 | PIK3CD (0.34) | PIK3CDMAPTNPC1RAB9A | |
| SCHEMBL31269460 | 0.90 | PIK3CD (0.34) | PIK3CDTHRBNPC1RAB9A | |
| SCHEMBL31269126 | 0.90 | PIK3CD (0.34) | PIK3CDMAPT | |
| SCHEMBL31268842 | 0.90 | PIK3CD (0.33) | PIK3CDNPC1RAB9A | |
| SCHEMBL31268974 | 0.90 | ALDH1A1 (0.35) | PIK3CDMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |